Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Wake Forest University Health Sciences
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01988571
The purpose of this research study is to see if Atorvastatin (Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in individuals receiving adjuvant anthracycline-based chemotherapy for breast cancer of lymphoma.
Intervention
Atorvastatin, Placebo
Condition
Breast Cancer, Lymphoma
Investigators
Gregory Hundley, MD

See list of participating sites